A minor comeback for Novartis’ Zelnorm.
Avandia gets a reprieve, of sorts…to remain on the market, but undoubtedly with a raft of warnings and cautions. Meanwhile, more encouraging data on Actos, which appears to avoid the Avandia effect. And was that data “covered up” earlier??
J&J to cut 4% of its workforce. Sanofi announces that its U.S. sales force has steadily declined, by 11%, over the past 2 years.
Bristol and ImClone to push oncology treatment Erbitux into expanded trials.
Combo pills – some fly high (Vytorin), others have a hard time getting off the ground.
The current figurehead for pharma whistleblowing, Dr. Peter Rost, gets a new assignment as a blogging journalist at Brandweek NRx.
Class action lawsuit against Novartis for bias against female employees will proceed.
Very cool – electrical stimulation device in brain “re-awakens” man in a minimally conscious state.
Leave a Reply